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902Objective: Neonatal cardiac surgery requiring cardiopulmonary bypass results in a heightened inflammatory
response. Perioperative glucocorticoid administration is commonly used in an attempt to reduce the inflamma-
tory cascade, although characterization of the cytokine response to steroids in neonatal cardiac surgery remains
elusive because of highly variable approaches in administration. This randomized trial was designed to prospec-
tively evaluate the effect of specific glucocorticoid dosing protocols on inflammatory markers in neonatal car-
diac surgery requiring cardiopulmonary bypass.
Methods:Neonates scheduled for cardiac surgery were randomly assigned to receive either 2-dose (8 hours pre-
operatively and operatively, n ¼ 36) or single-dose (operatively, n ¼ 32) methylprednisolone at 30 mg/kg per
dose in a prospective double-blind trial. The primary outcome was the effect of these steroid regimens on
markers of inflammation. Secondary analyses evaluated the association of specific cytokine profiles with post-
operative clinical outcomes.
Results: Patient demographics, perioperative variables, and preoperative indices of inflammation were similar
between the single- and 2-dose groups. Preoperative cytokine response after the 2-dose methylprednisolone pro-
tocol was consistent with an anti-inflammatory effect, although this did not persist into the postoperative period.
Premedication baseline levels of interleukin-6, interleukin-8, interleukin-10, and tumor necrosis factor a were
predictive of postoperative intensive care unit and hospital length of stay. Only interleukin-8 demonstrated
a postoperative response associated with duration of intensive care unit and hospital stay.
Conclusions: The addition of a preoperative dose of methylprednisolone to a standard intraoperative methyl-
prednisolone dose does not improve markers of inflammation after neonatal cardiac surgery. The routine admin-
istration of preoperative glucocorticoids in neonatal cardiac surgery should be reconsidered. (J Thorac
Cardiovasc Surg 2014;147:902-8)Earn CME credits at
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The Journal of Thoracic and Cardiovascular SurgCardiopulmonary bypass (CPB) is a complex pathophysio-
logic environment in which exposure to nonphysiologic
surfaces in the pump circuit, hemolysis, and ischemia-
reperfusion injury combine to initiate a complex cascade
that includes proinflammatory cytokines, anti-inflammatory
cytokines, and products of neutrophil activation.1-3 The
inflammatory consequences from CPB culminate in
a systemic inflammatory response syndrome. The systemic
inflammatory response syndrome is further exacerbated in
neonates because of morbidity factors of smaller patient
size, greater hemodilution, hypothermia, and longer CPB
times, resulting in a postoperative recovery period that is
longer and more complex than similar operations
performed in older infants and children.4-6
Clinical appreciation of this post-CPB inflammatory re-
sponse has resulted in several interventions directed toward
its reduction.7-9 Glucocorticoid administration is among the
most common method to attenuate the clinical and
biochemical features of the post-CPB inflammatory re-
sponse, although the technique of steroid administration in
neonatal cardiac surgery is highly variable.8,9 To furtherery c March 2014
Abbreviations and Acronyms
CPB ¼ cardiopulmonary bypass
ICU ¼ intensive care unit
IL ¼ interleukin
LCOS ¼ low cardiac output syndrome
MP ¼ methylprednisolone
TNF ¼ tumor necrosis factor
Graham et al Congenital Heart Disease
C
H
Dconfound matters, the few studies investigating clinical
outcomes associated with the use of corticosteroids in
children requiring CPB yield contradictory results.10-13
Given the intertwined and redundant inflammatory cas-
cade and the highly variable clinical practices in neonatal
preoperative and intraoperative care, characterizing the
anti-inflammatory response of steroids in neonatal cardiac
surgery has remained elusive. Accordingly, this randomized
trial was designed to prospectively evaluate the effect of
uniform and specific glucocorticoid dosing protocols on in-
flammatory markers in the context of neonatal cardiac sur-
gery requiring CPB.METHODS
Patient Selection, Enrollment, and Randomization
The study was approved by the Institutional Review Board, and in-
formed written consent was obtained from the parent or legal guardian in
accordance with all policies and regulations regarding obtaining informed
consent of a minor. The study was part of a clinical outcomes trial, and
the design details and clinical outcomes have been published
(ClinicalTrials.gov Identifier: NCT00934843).10 In brief, inclusion criteria
consisted of all inpatient neonates (aged 30 days) scheduled to undergo
a cardiac operation requiring CPB. Exclusion criteria included prematurity
(defined as36 weeks’ postmenstrual age) at the time of surgery, treatment
with steroids in the 2 weeks before surgery, suspected infection that would
contraindicate steroid use (eg, herpes), known hypersensitivity to methyl-
prednisolone (MP), or other contraindication to steroid therapy (eg, gastro-
intestinal tract bleeding). Subjects were randomly assigned to either
preoperative placebo (approximately 8 hours preoperatively) and intraoper-
ative MP at 30 mg/kg of body weight (single-dose group) or preoperative
and intraoperative MP (2-dose group) within strata, according to planned
corrective or palliative operation. All investigation and clinical site person-
nel were blinded to the treatment allocation until the close of the study.
Outcome Variables
The primary outcome was markers of inflammation after administration
of specific glucocorticoid dosing protocols. The correspondence of cytokine
profiles with clinical outcomes, such as low cardiac output syndrome
(LCOS) and intensive care unit (ICU) and hospital stays, was investigated
in secondary analyses. The presence of LCOS was defined by the clinicial
signs and symptomsof low cardiac output (eg, tachycardia, oliguria, cold ex-
tremities, and cardiac arrest) that require 1 ormore of the following interven-
tions: mechanical circulatory support, the escalation of exisiting
pharmacologic circulatory support to more than 100% over baseline, or
the inititation of new pharmacologic circulatory support.14 The determina-
tion of LCOS was made by 2 independent reviewers (E.M.G., A.M.A.)
and then agreed on between both reviewers before unblinding. Markers of
inflammation were compared between treatment groups, which included
the plasma levels of the proinflammatory cytokines, interleukin (IL)-2,The Journal of Thoracic and CaIL-6, IL-8, tumor necrosis factor a (TNF-a), and interferon-g, and the
anti-inflammatory cytokine, IL-10. The rationale for the selection of these
cytokines was to survey both proinflammatory and anti-inflammatory
markers. Sampleswere collected at 6 timepoints: (1) ‘‘baseline,’’ before pre-
operative placebo/MP treatment (approximately 8 hours preoperatively), (2)
immediately before skin incision, (3) on completion of modified ultrafiltra-
tion, and at (4) 4 hours, (5) 12 hours, and (6) 24 hours postoperatively.Whole
blood samples of 1 mL were collected in ethylenediaminetetraacetic acid
tubes at each of the 6 timepoints. Plasmawas isolated by centrifugation, dec-
anted into aliquots, and stored at80C until processed for immunoassays.
Plasma levels of cytokines were determined bymultiplex suspension array
using commercially available and validated kits (R&D Systems,Minneapolis,
Minn).3 Plasma values were corrected for hemodilution using hematocrit
values. All samples were batched and run simultaenously to avoid potential
laboratory assay variance. Patients enrolled in the parent study were included
in this analysis if they had an adequate volume of plasma at each of the 6 time
points to analyzeall inflammatorymarkers. Plasma-freehemoglobin, as amea-
surement of hemolysis, was obtained postoperatively on arrival to the ICU.
Statistical Analysis
Standard descriptive statistics were used to summarize the general demo-
graphic and clinical data.Continuous demographic characteristics are listed as
means and associated SDs and were compared between groups using a t-test.
Categorical characteristics are expressedas the number andpercentage of sub-
jects and were compared using a normal Pearson c2 test statistic. Because of
their skeweddistributions, baselinemeasures of inflammatorymarkers are ex-
pressed as the median and interquartile range and are compared across steroid
groups using a Wilcoxon rank-sum test statistic. Preoperative indices of in-
flammation were measured at ‘‘baseline’’ before administration of the preop-
erative steroids (or placebo) and again before surgery (preincision). To
appraise the pharmacologic effect of preoperative MP steroid dose on cyto-
kine levels, an analysis of variance model was used, fitting the preoperative
steroid levels while controlling for the baseline premedication levels.
To assess the effect of steroid treatment on the cytokine profiles after
surgery, a linear mixed-effect model was used. Restricted maximum likeli-
hood methods were used to estimate the fixed effects and variance compo-
nents in the presence of unbalanced data.15 Baseline cytokine values
(premed), randomized treatment assignment, and aprotinin use status
were used as covariates in a regression model, and estimate statements
were used to construct group-level mean tests across steroid treatment
groups at each time point. All cytokine post hoc pairwise comparison re-
sults are adjusted using the Bonferonni method. Because of the highly
skewed and nonnormal distributions of the markers of inflammation, the
values were log10 transformed before model analysis.
To test whether baseline or peak cytokine levels are associated with clin-
ical postoperative outcomes (ICU and hospital lengths of stay), regression
models were developed that adjusted for study design variables (random-
ized steroid treatment group and aprotinin administration). Independent as-
sociations were present between sex and surgery type (corrective vs
palliative) with both ICU and hospital lengths of stay. Thus, all regression
models were additionally adjusted for both characteristics. To test whether
increases in baseline or peak cytokine levels are associated with higher
odds to develop postoperative LCOS, similarly adjusted logistic regression
models were developed. Statistical analyses were performed with SAS,
version 9.2 (SAS Institute, Inc, Cary, NC).RESULTS
Preoperative Demographics and Intraoperative
Variables
Enrollment and outcomes have been previously reported.10
Briefly, 97 patients were screened for enrollment, and 78
met all inclusion/exclusion criteria and were randomized.rdiovascular Surgery c Volume 147, Number 3 903
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were excluded postrandomization. The remaining 76 random-
ized patientswere assigned to the preoperative placebo and in-
traoperative MP (single dose, n ¼ 37) or preoperative and
intraoperative MP (2 dose, n ¼ 39) protocol. Of the 76 sub-
jects in the parent study, 68 had inflammatory markers mea-
sured at all 6 time points and were included in this analysis
(single dose, n ¼ 32; 2 dose, n ¼ 36). Patient demographics,
cardiac diagnoses, clinical characteristics, and operative and
immediate postoperative procedures were similar between
groups (Table 1). Similarly, overall CPB times, cross-clamp
times, the use of deep hypothermic circulatory arrest, and im-
mediate postoperative procedures were similar between the
groups and have been previously reported.10 Mean plasma-
free hemoglobin levels on arrival to the ICU were 71  36
mg/dL in the single-dose group and 75  40 mg/dL in the
2-dose group (P ¼ .69).Preoperative Indices of Inflammation
Before study drug administration, baseline cytokine levels
were similar between groups (Table 1). Immediately before
skin incision, the proinflammatory cytokine IL-6 and TNF-
a values decreased by 40% or more (P<.01) (Figure 1, ATABLE 1. Preoperative demographics and clinical characteristics in neona
or 2-dose methylprednisolone strategy
Baseline demographic and clinical characteristics MP single
Demographics
Gestational age at birth, wk 38
Gestational age at surgery, wk 39
Age at surgery, d 7.
Aged 7 d, no. (%) 25
Weight at surgery, kg 3.
Prenatal diagnosis, no. (%) 14
Male sex, no. (%) 16
Markers of inflammation, pg/mL
IL-2 1.1
IL-6 6.7
IL-8 22
IL-10 1.2
TNF-a 6.8
IFN-g 0.10
Diagnosis
Corrective Procedure 17
Aortic arch hypoplasia with VSD
Tetralogy of Fallot
Transposition of the great arteries
Truncus arteriosis
Other biventricular repair
Palliative Procedure 15
Hypoplastic left heart syndrome
Other single-ventricle lesions
Pulmonary atresia with intact ventricular septum
Tetralogy of Fallot with pulmonary atresia
Data are reported as mean  SD, number (%), or median (interquartile range), as approp
terferon; VSD, ventricular septal defect.
904 The Journal of Thoracic and Cardiovascular Surgand D) and the anti-inflammatory cytokine IL-10 value in-
creased nearly 5-fold in the 2-dose group (P < .01)
(Figure 1, C), consistent with a pharmacologic effect of the
preoperative MP dose. A pharmacologic response to preoper-
ativeMP occurred in most patients in the 2-dose group, as ev-
ident by 92% (33/36) having a decline in IL-6 levels between
these preoperative time points. Although absolute IL-8 values
before skin incision were similar between groups, when ad-
justed for baseline values, therewas a significant effect of pre-
operative MP administration (P<.01) (Figure 1, B). IL-2 and
interferon-gwere low at baseline (Table 1) and not affected by
preoperative MP administration.Postoperative Indices of Inflammation
Dynamic changes in cytokine levels occurred in the post-
operative period, indicative of altered inflammatory re-
sponse in neonatal cardiac surgery. Robust increases in
the proinflammatory responses of IL-6 and IL-8 occurred
in the early postoperative period in both groups (P<.01).
These increases were similar between the single- and
2-dose groups (Figure 1). Immediately after modified ultra-
filtration, IL-6 levels in the single-dose group remained
numerically, but not significantly, higher than in thetal patients undergoing cardiac surgery, randomized to either a single-
dose (n ¼ 32) MP 2 dose (n ¼ 36) P value
.4  1.4 38.9  1.2 .21
.5  1.4 40.1  1.5 .08
7  4.3 8.7  5.3 .27
(78) 22 (61) .13
1  0.5 3.3  0.5 .37
(44) 18 (50) .61
(50) 20 (56) .65
(0.9-1.3) 1.2 (1.0-1.3) .15
(3.5-9.4) 8.8 (3.7-21.2) .33
(17-42) 31 (19-47) .25
(0.8-2.1) 1.4 (0.9-2.4) .45
(4.1-8.7) 5.9 (4.2-8.2) .56
(0.09-0.12) 0.11 (0.10-0.13) .19
(53) 19 (53) .97
3 5
2 2
9 9
1 2
2 1
(47) 17 (47)
5 8
8 7
0 2
2 0
riate. MP, Methylprednisolone; IL, interleukin; TNF, tumor necrosis factor; IFN, in-
ery c March 2014
FIGURE 1. Cytokine profile at baseline (atMeds) and response to methylprednisolone (MP) or placebo before cardiopulmonary bypass (CPB; preincision)
and after CPB (0, 4, 12, and 24 hours after surgery) compared between treatment groups for logarithm-transformed values of (A) interleukin (IL)-6, (B) IL-8,
(C) IL-10, and (D) tumor necrosis factor (TNF)-a. *P<.05 (Bonferonni adjusted). Hr, Hour; MP, methylprednisolone.
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IL-10, also had a significant increase in the postoperative
period in both groups (P < .01) and was higher in the
2-dose group immediately after modified ultrafiltration
(P ¼ .001) (Figure 1, C), but was similar to the single-
dose group at all other postoperative time points. The pleo-
tropic molecule, TNF-a, was higher in the single-dose
group immediately before CBP but failed to maintain this
difference for the duration of the postoperative follow-up.Preoperative Indices of Inflammation and Outcomes
Baseline indices of a heightened inflammatory state were
associated with clinical postoperative outcomes of interest.
Of the 68 study participants, 29 (43%) experienced LCOS.
For the entire cohort, mean ICU length of stay was 11.3 days
(SD, 16.5 days) and hospital stay was 23.5 days (SD, 21.1
days), with no difference in these clinical outcomes between
treatment groups. Higher levels of IL-6, IL-8, and IL-10 at
baseline were significantly associated with increased post-
operative ICU and hospital lengths of stay (all P< .04)
(Table 2). Increased levels of TNF-a at baseline were mod-
estly associatedwith ICU (P¼ .057) and hospital (P¼ .044)
lengths of stay. None of the baseline cytokine measures was
associated with LCOS after surgery (all P>.15).Postoperative Indices of Inflammation and Outcomes
Despite the association of baseline levels of cytokines
with clinical outcomes, a similar association for most post-
operative values was not statistically significant. TheThe Journal of Thoracic and Capostoperative response of the proinflammatory cytokine,
IL-8, was predictive of ICU and hospital stays (b ¼ .33
and b ¼ .26, respectively; P< .001) (Table 2). None of
the other postoperative measured cytokines was predictive
of outcomes. In addition, no peak cytokine response was
predictive of LCOS.DISCUSSION
This prospective, randomized study using 2 different MP
dosing strategies yielded a balanced set of patients in each
treatment arm and, thereby, provided control for several
potentially confounding variables. The unique findings are
3-fold. First, although the 2-dose MP protocol reduced
preoperative proinflammatory cytokines and increased
anti-inflammatory cytokine levels, consistent with an anti-
inflammatory effect, this effect did not persist into the post-
operative period. Second, premedication baseline levels of
IL-6, IL-8, IL-10, and TNF-a were associated with in-
creased postoperative ICU and hospital lengths of stay.
Third, although the baseline levels of several cytokines
were predictive of postoperative outcomes, only the postop-
erative response of the proinflammatory cytokine, IL-8, was
associated with an increased duration of ICU and hospital
stays. None of the other cytokines measured was associated
with LCOS or ICU or hospital stays. The results from this
randomized MP dosing protocol indicate that preoperative
glucocorticoid treatment does not improve early postopera-
tive markers of inflammation in neonatal cardiac surgery
when compared with a single intraoperative dose. Theserdiovascular Surgery c Volume 147, Number 3 905
TABLE 2. Association between baseline and peak measures of inflammation with postoperative outcomes
Measures of inflammation
Postoperative outcomes
ICU length of stay Hospital length of stay Low cardiac output syndrome
b ± SE P value b ± SE P value OR (95% CI) P value
Baseline levels
Log10 IL-6 0.14  0.06 .039 0.18  0.05 <.001 0.49 (0.18-1.34) .162
Log10 IL-8 0.28  0.09 .002 0.19  0.07 .012 1.54 (0.43-5.52) .510
Log10 IL-10 0.23  0.09 .017 0.20  0.08 .013 0.55 (0.14-2.17) .395
Log10 TNF-a 0.33  0.17 .057 0.29  0.14 .044 3.81 (0.33-43.8) .293
Postoperative levels
Log10 IL-6 0.08  0.09 .364 0.06  0.08 .414 1.15 (0.33-4.04) .822
Log10 IL-8 0.33  0.09 <.001 0.26  0.08 <.001 2.39 (0.61-9.38) .213
Log10 IL-10 0.02  0.07 .792 0.03  0.06 .585 1.24 (0.47-3.29) .664
Log10 TNF-a 0.11  0.12 .371 0.16  0.10 .119 0.61 (0.12-3.26) .564
Preoperative levels of inflammation were measured before administration of study medication. Postoperative levels include the peak results measured after surgery. All analysis
results shown are adjusted for study design variables (steroid treatment assignment and aprotinin administration), sex, and surgery type. Both ICU and hospital lengths of stay
were highly skewed and were also log10 transformed before analysis. b Estimates frommixed-effects linear models are shown as b SE, and logistic regression results are shown
as OR (95% CI). ICU, Intensive care unit; OR, odds ratio; CI, confidence interval; IL, interleukin; TNF, tumor necrosis factor.
Congenital Heart Disease Graham et al
C
H
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widespread use of glucocorticoids in these high-risk cardiac
surgery patients would be appropriate.
Glucocorticoid Dosing Strategies and Inflammatory
Mediators: Past Studies
Glucocorticoids exert their anti-inflammatory effects
through a complex series of both genomic and nongenomic
effects. The classic genomic mechanism of glucocorticoids
is activated via the cytosolic glucocorticoid receptor, result-
ing in both increased expression of anti-inflammatory regula-
tory proteins and decreased production of proinflammatory
proteins.16 The modification of gene expression requires
hours to days for clinical effects, founding the hypothesis
for steroid administration 8 to 12 hours before CPB.17
Some rapid clinical effects occur too promptly to be ex-
plained by a genetic mode of action, and have been attributed
to nongenomic mechanisms, including specific interaction
with the cytosolic glucocorticoid receptor, nonspecific inter-
actions with cellular membranes, and specific interactions
with membrane-bound glucocorticoid receptors.18
Glucocorticoid administration has been associated with
unclear benefits and potential detrimental effects in both
adults and children undergoing cardiac surgery. Despite
this, there is widespread use of perioperative glucocorticoid
administration in pediatric cardiac surgery, with 80% to
97% of centers using some form of glucocorticoid ther-
apy.8,9 Few controlled trials of glucocorticoids in the
setting of CPB in pediatrics can be found. Bronicki and
colleagues19 randomized 29 children (mean age, 28
months) to receive dexamethasone (1 mg/kg, n¼ 15) or pla-
cebo (n ¼ 14) 1 hour before CPB. Similar to our findings,
both groups demonstrated a significant elevation in IL-6 af-
ter CPB. However, dexamethasone-treated patients had
a blunted IL-6 response when compared with placebo.906 The Journal of Thoracic and Cardiovascular SurgThe authors reported an increase in TNF-a 2 minutes after
CPB in the placebo group. It remained more than 3 times
higher 10 minutes after protamine administration in the pla-
cebo group, but this did not reach statistical significance. At
24 hours postoperatively, the mean values were virtually
identical. Complement component C3a and absolute neu-
trophil count were not affected by dexamethasone.
Lindberg and colleagues20 randomized 40 patients weigh-
ing more than 10 kg (mean age, 52 months) to receive dexa-
methasone (1 mg/kg, n ¼ 20) or placebo (n ¼ 20) after the
induction of anesthesia. C-reactive protein, as a marker of in-
flammation,was lower in the treatment group on the first post-
operative day. In this cohort, we have previously reported
similar levels of C-reactive protein at 36 hours postopera-
tively between the single- and 2-dose groups.10 Schroeder
and colleagues21 randomized 29 children (mean age, 4
months) to MP (30 mg/kg, n ¼ 15) or placebo (n ¼ 14) 4
hours before CPB. Similar to our study, MP (30 mg/kg)
was administered in the pump prime in all patients. Serum
IL-6 was lower immediately and 4 hours after CPB in the
combined MP compared with the intraoperative-only group,
butwas equally elevated in both groups by 24 hours. The anti-
inflammatory cytokine, IL-10, was elevated in the combined
MP group at the end of CPB and returned to baseline in both
groups by 24 hours, similar to this study. Interestingly, they
measured RNA from atrial samples before and after CPB.
Both groups had an increased expression of inflammatory
mediators after CPB; however, the combined steroid group
had a statistically significant reduction in the expression of
regulated on activation normal T cell expressed and secreted,
monocyte chemoattractant protein-1, IL-6, and intercellular
adhesionmolecule-1. Patients receiving preoperative steroids
also had lowermRNA expression formonocyte chemoattrac-
tant protein-1, IL-6, and intercellular adhesion molecule-1 at
bypass initiation, before myocardial ischemia.ery c March 2014
Graham et al Congenital Heart Disease
C
H
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leagues22 randomized 30 children (mean age, 48 months)
to receive either high-dose MP (30 mg/kg) or low-dose
MP (2 mg/kg) before the onset of CPB. Consistent with
the findings of this study, plasma levels of IL-6, IL-8, C-re-
active protein, and polymorphonuclear leukocyte counts
were all elevated postoperatively in both groups, without
a significant difference between groups.
Inflammatory Response and Clinical Outcomes
Few studies in neonates and infants can be found demon-
strating a relationship between inflammatory mediators and
postoperative recovery. Consistent with this study, Alcaraz
and colleagues6 investigated 8 neonates and 19 infants un-
dergoing CPB and demonstrated significant increases in
IL-6, IL-8, and TNF in both groups postoperatively. The
magnitude of the inflammatory response was greater in
the neonates, particularly for IL-8. Moreover, the IL-8
response correlated with pulmonary dysfunction and longer
ICU stay. In contrast, IL-6 and TNF response was not asso-
ciated with clinical outcomes. In a larger study by Allan and
colleagues,4 the authors demonstrated in 93 infants, 9
months or younger, undergoing low-to-moderate complex-
ity cardiac surgery serum concentrations of IL-6 and IL-8
immediately after CPB and at 24 hours postoperatively,
these were associated with ICU length of stay in multivari-
ate analysis. However, despite reaching statistical signifi-
cance, the variability in outcomes accounted for by these
inflammatory mediators was only of modest clinical signif-
icance (4%-9% variability of a median ICU stay of 3 days).
Furthermore, despite demonstrating a heightened preopera-
tive inflammatory state in the neonatal population, this did
not correlate with postoperative markers of inflammation
or clinical outcomes. The authors concluded that, in infants
undergoing low-to-moderate complexity cardiac surgery,
the contribution of inflammatory mediator production to
postoperative morbidity is relatively limited.
In contrast, Appachi and colleagues23 demonstrated that
neonates with hypoplastic left heart syndrome had higher
preoperative and postoperative IL-6 levels than those with
transposition of the great arteries, and postoperative IL-6
concentration was associated with mortality in neonates
with hypoplastic left heart syndrome. This work suggests
that the inflammatory response may have a greater signifi-
cance in more complex operations. However, unique to
the current study is the sole inclusion of neonates, resulting
in the inclusion of complex corrective and palliative opera-
tions and the potential increased morbidity associated with
them.
Study Limitations
Limitations of the current study include the lack of
a completely placebo group. Therefore, it remains unclear
whether the dosing strategies used were equally effectiveThe Journal of Thoracic and Caor neither was effective. Thus, recommendations for or
against intraoperative MP cannot be made. Given the theo-
retical benefits and thewidespread use of intraoperative glu-
cocorticoids, a completely placebo arm was thought to be
inapproriate during the design of this study. Considered in
total, the past and present studies highlight the need for a re-
cently initiated randomized controlled trial comparing intra-
operative glucocorticoids with placebo in neonatal cardiac
surgery (ClinicalTrials.gov identifier: NCT01579513). The
results of our trial do not preclude the efficacy of other
glucocorticoid regimens or the potential importance of other
inflammatory pathways that were not directly examined in
this study.CONCLUSIONS
In conclusion, in the largest pediatric and only exclu-
sively neonatal randomized trial comparing the efficacy of
preoperative glucocorticoid therapy with intraoperative glu-
cocorticoid therapy alone for neonates undergoing correc-
tive and palliative cardiac operations requiring CPB, our
data do not provide support for the addition of a preoperative
dose of MP to a standard intraoperative dose alone. Al-
though preoperative dosing was associated with an im-
provement in preoperative inflammatory markers, this did
not persist in the postoperative period. In light of these
findings, the routine use of preoperative glucocorticoids in
neonatal cardiac surgery needs to be reconsidered. Alterna-
tive therapies, not necessarly directed at anti-inflammatory
mediators, are needed.References
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